Paper Details

  1. Home
  2. Paper Details

A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893).

Author: ArchimbaudE, BernemanZ, DardenneM, DohnerH, JaksicB, JehnU, LabarB, LouwagieE A, MuusP, StryckmansP, SuciuS, TjeanM, WijermansP, WillemzeR, ZittounR

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

A combination therapy with 5-Aza-2'-deoxycytidine and either amsacrine or idarubicin achieved a complete remission in 36.5% of patients with relapsed acute myeloid or lymphocytic leukemia. While effective, this treatment had prolonged digestive tract and hematologic toxicity. Further investigation is needed in previously untreated leukemia.
Paper Details　
Original Abstract of the Article :
5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin has been applied in a treatment protocol for patients with a relapse of acute myeloid or lymphocytic leukemia. Sixty-three patients received 5-Aza-2'-deoxycytidine 125 mg/m2 as a 6 h infusion every 12 h for 6 days in combination wit...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/9130688

データ提供：米国国立医学図書館（NLM）

Relapsed Leukemia: A New Oasis in the Desert of Treatment Options

Imagine a vast desert where relapsed leukemia is like a relentless sandstorm, threatening the lives of patients. This research explores a promising new treatment strategy for relapsed leukemia, combining the drugs 5-Aza-2'-deoxycytidine with either amsacrine or idarubicin.

The researchers conducted a randomized phase II study to evaluate the effectiveness of this combination therapy, meticulously analyzing the treatment outcomes and side effects. This is like meticulously mapping out a new route through the desert, searching for safer and more effective ways to navigate a challenging landscape.

A New Path for Relapsed Leukemia

The study reveals that this combination therapy can induce complete remission in a significant number of patients with relapsed leukemia, offering a new hope for those struggling with this devastating disease. It's like discovering a hidden oasis in the desert, providing much-needed relief and a chance for recovery.

Health Implications and Practical Tips

This study provides a beacon of hope in the desert of leukemia treatment. It highlights the power of ongoing research and innovation in finding new ways to combat this challenging disease. However, as always, it's crucial to be aware of potential side effects and work closely with healthcare professionals to manage any risks.

Dr.Camel's Conclusion

This research offers a new path for patients with relapsed leukemia, demonstrating the potential of combining drugs to improve treatment outcomes. Like a patient traveler, we must remain optimistic and vigilant, exploring new treatment options and working tirelessly to find solutions to challenging diseases.

Date :
  1. Date Completed 1997-05-22
  2. Date Revised 2018-11-30
Further Info :

Pubmed ID

9130688

DOI: Digital Object Identifier

9130688

Related Literature

Article Analysis
・Effects of idarubicin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.